4D Molecular Therapeutics (FDMT) Shares Outstanding (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Shares Outstanding (Entity) of $68.1 million for Q1 2026, up 46.93% year-over-year from $46.3 million in Q1 2025, and up 18.15% quarter-over-quarter from $57.6 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Shares Outstanding (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Shares Outstanding (Entity) for 8 consecutive years, with $68.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 46.93% year-over-year to $68.1 million; the TTM figure through Mar 2026 stood at $68.1 million (up 46.93% YoY), while the FY2025 annual figure was $57.6 million, up 25.8% from the prior year.
- Shares Outstanding (Entity) climbed to $68.1 million in Q1 2026 per FDMT's latest filing, from $57.6 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $68.1 million in Q1 2026 and bottomed at $32.3 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $44.5 million across 5 years, with a median of $45.8 million in 2024.
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) jumped 53.92% — and 2025, when it retreated 10.05%.
- 4D Molecular Therapeutics' Shares Outstanding (Entity) stood at $32.6 million in 2022, then soared by 32.02% to $43.1 million in 2023, then grew by 6.31% to $45.8 million in 2024, then advanced by 25.8% to $57.6 million in 2025, then grew by 18.15% to $68.1 million in 2026.
- Business Quant data shows FDMT's Shares Outstanding (Entity) at $68.1 million in Q1 2026, $57.6 million in Q4 2025, and $46.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 70.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 70.27 Mn |
| Mar 31, 2026 | 68.06 Mn |
| Dec 31, 2025 | 57.93 Mn |
| Sep 30, 2025 | 56.13 Mn |
| Jun 30, 2025 | 55.93 Mn |
| Mar 31, 2025 | 55.74 Mn |
| Dec 31, 2024 | 53.94 Mn |
| Sep 30, 2024 | 55.55 Mn |
| Jun 30, 2024 | 55.28 Mn |
| Mar 31, 2024 | 49.27 Mn |
| Dec 31, 2023 | 39.13 Mn |
| Sep 30, 2023 | 42.26 Mn |
| Jun 30, 2023 | 38.34 Mn |
| Mar 31, 2023 | 32.72 Mn |
| Dec 31, 2022 | 32.35 Mn |
| Sep 30, 2022 | 32.39 Mn |
| Jun 30, 2022 | 32.32 Mn |
| Mar 31, 2022 | 32.23 Mn |
| Dec 31, 2021 | 27.73 Mn |
| Sep 30, 2021 | 27.02 Mn |